{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:06:44Z","timestamp":1777428404126,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[1990,5,1]],"date-time":"1990-05-01T00:00:00Z","timestamp":641520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Clin Biochem"],"published-print":{"date-parts":[[1990,5]]},"abstract":"<jats:p>An external quality assessment survey of testing facilities in UK clinical laboratories for the detection of drugs of abuse was made with nine freeze-dried samples of urine containing representative drugs with their metabolites from the following seven classes; amphetamines and stimulants, barbiturates, cannabinoids, cocaine, minor tranquillisers, opiates and non-opiate narcotics. Reports were received from 120 laboratories. Thirty six per cent of laboratories reported on all seven drug classes and 71% on the five classes excluding cannabinoids and cocaine. A single drug screening technique was used by 32% of laboratories whilst 46% were able to perform tests by both immunological and chromatographic techniques. There was a mean level of false positive reporting of 4\u00b73% and an observed level of false negative reports of 8\u00b74%, the latter underestimating the true frequency. The minor tranquillisers, cocaine and benzoyl ecgonine were the most frequently missed analytes. Several false reports had important potential implications for patient care.<\/jats:p>","DOI":"10.1177\/000456329002700306","type":"journal-article","created":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T16:58:39Z","timestamp":1391619519000},"page":"213-222","source":"Crossref","is-referenced-by-count":11,"title":["A Survey of Drugs of Abuse Testing by Clinical Laboratories in the United Kingdom"],"prefix":"10.1177","volume":"27","author":[{"given":"D","family":"Burnett","sequence":"first","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Lader","sequence":"additional","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Richens","sequence":"additional","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B L","family":"Smith","sequence":"additional","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P A","family":"Toseland","sequence":"additional","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Walker","sequence":"additional","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Williams","sequence":"additional","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J F","family":"Wilson","sequence":"additional","affiliation":[{"name":"Steering Committee for the UK-External Quality Assessment Scheme for Therapeutic Drug Assays"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1990,5,1]]},"reference":[{"key":"bibr1-000456329002700306","volume-title":"Guidelines of Good Clinical Practice in the Treatment of Drug Misuse. Report of the Medical Working Group on Drug Dependence","author":"Department of Health and Social Security","year":"1984"},{"key":"bibr2-000456329002700306","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/34.3.605"},{"key":"bibr3-000456329002700306","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/33.9.1683"},{"key":"bibr4-000456329002700306","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/35.5.891"},{"key":"bibr5-000456329002700306","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/35.5.879"},{"key":"bibr6-000456329002700306","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1967.tb08089.x"},{"key":"bibr7-000456329002700306","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/12.3.147"}],"container-title":["Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/000456329002700306","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/000456329002700306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:36:08Z","timestamp":1777376168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/000456329002700306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,5]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1990,5]]}},"alternative-id":["10.1177\/000456329002700306"],"URL":"https:\/\/doi.org\/10.1177\/000456329002700306","relation":{},"ISSN":["0004-5632","1758-1001"],"issn-type":[{"value":"0004-5632","type":"print"},{"value":"1758-1001","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,5]]}}}